Yes, imiquimod 5% cream can be applied to the face.
Imiquimod 5% cream is specifically licensed and indicated for use on the face (and scalp) for treating actinic keratoses in immunocompetent adults. 1, 2
Licensing and Approved Facial Use
The FDA drug label explicitly states that imiquimod cream is indicated for "the topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses on the face or scalp in immunocompetent adults" 2. The British Association of Dermatologists guidelines (2017) confirm this, noting it is licensed for use on "the face or scalp" with a strength of recommendation A and level of evidence 1++ 1.
Application Details for Facial Use
For actinic keratoses on the face:
- Treatment area: One contiguous area of approximately 25 cm² (e.g., 5 cm × 5 cm) on the face, such as the forehead or one cheek 2
- Frequency: 2 times per week for 16 weeks (e.g., Monday and Thursday) 2
- Application method: Apply at night, leave on for approximately 8 hours, then wash off with mild soap and water 1, 2
- Important precautions: Avoid contact with eyes, lips, and nostrils 2
Evidence Supporting Facial Use
Multiple randomized controlled trials have demonstrated efficacy specifically for facial application:
- Meta-analysis of five RCTs showed 50% complete clearance rate when used 2-3 times per week for 12-16 weeks 1
- Studies specifically evaluated treatment on "face or scalp" with clearance rates ranging from 47-84% 1, 3
- Lower concentration formulations (2.5% and 3.75%) have also been studied for daily application to the "full face or balding scalp" with complete clearance rates of 30.6-35.6% 4
Important Caveats for Facial Application
Local inflammatory reactions are common and expected on facial skin, including erythema, weeping, or erosion 2. These reactions may require treatment interruption but are generally well-tolerated when patients are properly counseled 1. The face is considered a "sensitive area" where such reactions should be anticipated 1.
Avoid periorbital application with caution: While the face is approved, the guidelines note that topical therapies "can be difficult to use near mouth and eyes" 5, and the drug label specifically warns to avoid contact with eyes, lips, and nostrils 2.
Sun protection is mandatory: Patients must minimize sun exposure during treatment as imiquimod increases sunburn susceptibility and has been shown to shorten time to skin tumor formation in animal studies 2.